for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Jemperli, intended for the treatment of certain types of recurrent or advanced endometrial cancer. The applicant for this medicinal product is GSK (Ireland) Limited. Dostarlimab was approved for medical use in the European Union in April 2021. Economics In the United States, dostarlimab costs around per dose. Among those who are insured, those who have Medicaid insurance are less likely to receive full care for gynecologic cancer. Those insured through private insurance still experience economical hardships while getting treatment. Uninsured patients do not tend to get screened regularly, which results in late diagnosis of the disease. References Further reading External links Breakthrough therapy GSK plc brands Monoclonal antibodies for tumors